19 (PB005) - DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations

Natalie Ngoi ,P.G Pilie,A Johnson,C Salguero,W.E Hoadley,S Fu,C.V Brown,S.N Westin,Y Yuan,S.A Piha-Paul,Jordi Rodón Ahnert ,A Naing ,S Pant ,E.e Dumbrava ,V Subbiah ,A.m Tsimberidou ,D.d Karp ,D.s Hong ,F Meric-Bernstam ,T.a Yap

doi:10.1016/s0959-8049(22)00828-0

19 (PB005) - DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial: Phase 1/2 Study of the ATR inhibitor (ATRi) berzosertib and PD-L1 inhibitor avelumab in patients (pts) with advanced solid tumors with DDR molecular alterations

Natalie Ngoi , P.G Pilie + Show 18 more

Open Access

https://doi.org/10.1016/s0959-8049(22)00828-0

Copy DOI

Journal: European Journal of Cancer	Publication Date: Oct 1, 2022
Citations: 1

Affiliation: The University of Texas MD Anderson Cancer Center

#PD-L1 Inhibitor Avelumab #DNA Damage Response + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background: ATR is a central kinase involved in the DDR and replication stress response (RSR) and innate immune activation. This is the first report of the investigator-initiated phase 1/2 D-BOB trial (NCT04266912), funded by EMD Serono (CrossRef Funder ID: 10.13039/100004755).

Full Text